Home › GE Healthcare Files Supplemental New Drug Application For Its Own Manufacturing Of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)
 

Keywords :   


GE Healthcare Files Supplemental New Drug Application For Its Own Manufacturing Of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)

2013-01-15 13:50:00| drugdiscoveryonline News Articles

GE Healthcare recently announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility

Tags: application files drug manufacturing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 4
29.06Tropical Storm Beryl Wind Speed Probabilities Number 4
29.06Tropical Storm Beryl Public Advisory Number 4
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Forecast Advisory Number 4
29.06Tropical Storm Beryl Public Advisory Number 3A
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
More »